Tracers / [111In]3p-C-NETA-ePSMA-16
[111In]3p-C-NETA-ePSMA-16
Also written as [In-111]In-3p-C-NETA-ePSMA-16
- Radionuclide
- In-111 t½ 4031.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- PSMA-targeting NETA-based bifunctional chelator conjugate (PSMA-targeting radiotheranostic agent)
- Target / mechanism
- PSMA (prostate-specific membrane antigen) PMID 37375829
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | 99.7 ± 0.2% | >99% | 3p-C-NETA-ePSMA-16 | 37375829 2023 Pharmaceuticals (Basel) Radiolabeling with 111In afforded quantitative radiochemical yield (RCY) (99.7 ± 0.2%, n = 5) in mild conditions (rt, 5 min) — Radiolabeling with 111In afforded quantitative radiochemical yield (RCY) (99.7 ± 0.2%, n = 5) |
Need this precursor?We can point you to suppliers for [111In]3p-C-NETA-ePSMA-16, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37375829. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37375829: '3p-C-NETA-ePSMA-16 (1 nmol) dissolved in H2O was added to the solution'.